Datroway FDA Approval for First-Line Metastatic TNBC
Review the FDA approval of Datroway (datopotamab deruxtecan) for first-line metastatic TNBC. Analyze TROPION-Breast02 efficacy, survival, and safety data.
Back to Articles
Articles tagged with “oncology”
Relacorilant: FDA Approved GR Antagonist for Ovarian Cancer
Review the FDA approval of relacorilant (Lifyorli) for platinum-resistant ovarian cancer. Learn its clinical efficacy and mechanism as a GR antagonist.
Vepdegestrant FDA Approval: First PROTAC for Breast Cancer
Review the 2026 FDA approval of vepdegestrant (Veppanu), the first PROTAC targeted protein degrader for ESR1-mutated breast cancer, and its clinical data.
Biomarker Testing Coordination Services: An Oncology Guide
Updated 2026 guide to biomarker testing coordination services in oncology. Covers navigator roles, FDA companion diagnostic reclassification, liquid biopsy adoption, NCCN guideline updates, and AI-driven diagnostics for precision medicine.
How to Handle Payer Objections in the U.S. Oncology Market: A Comprehensive Guide
Practical guide for Market Access teams and field representatives on handling common payer objections in oncology, including strategies for verbal and written communications, real-world examples, and response frameworks.